China's leading domestic maker of recombinant human insulin and diabetes-care products.
China's leading domestic maker of recombinant human insulin and diabetes-care products.
Sells insulin mostly to public hospitals and pharmacies, with prices set largely by government tenders; national volume-based procurement of insulin began in 2022. Shifting prescriptions from older human insulin to newer analogue insulins and pens is a key theme.
In one line: A Chinese Novo Nordisk (insulin), at smaller scale.
Moat: narrow (scale, regulatory licence, brand). Largest domestic insulin manufacturing scale and long-standing physician/hospital relationships.
Headquarters: Tonghua, Jilin, China · Employees: 3,354
Size Tonghua Dongbao Pharmaceutical (600867.SS) is a China Health Care company (Pharmaceuticals: Major) with a market value of $2.19B, the 1092nd largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥7.65 on 18 Nov 2026.
Performance Over six months the shares fell 12.4%, against +2.3% for the median peer and -20.0% for the China market (cap-weighted) — 8th lowest of 21 in its peer set.
Growth Revenue grew 18.3% over the last twelve months (peer median +4.7%).
Valuation It trades at 25.4× forward earnings against a peer median of 17.5× (6th most expensive of 15).
Price implies For today's price to make sense, revenue must grow about 1% a year for seven years (Req g). Recent delivered growth is 0%, so the hurdle is +1 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Next results Next results expected around 22 Apr 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥3.24B | CN¥2.94B | CN¥2.00B | CN¥3.07B | CN¥2.77B |
| Revenue growth | — | +47% | -35% | +11% | — |
| Gross profit | n/a | CN¥1.96B | CN¥1.37B | CN¥2.38B | CN¥2.08B |
| EBITDA | n/a | CN¥884M | CN¥319M | CN¥1.48B | CN¥1.05B |
| Net income | CN¥542M | CN¥1.22B | -CN¥42.0M | CN¥1.17B | CN¥1.58B |
| Free cash flow | CN¥628M | CN¥213M | -CN¥73.1M | CN¥537M | CN¥392M |
| Capital expenditure | CN¥506M | CN¥518M | CN¥569M | CN¥348M | CN¥493M |
| Total debt | CN¥659M | CN¥612M | CN¥697M | CN¥150M | CN¥2.65M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Tonghua Dongbao Pharmaceutical 600867.SS | $2.19B | -12% | +18% | n/a | 25.4× | 0.9% |
| Novo Nordisk A/S NOVO-B.CO | $177B | -6% | +6% | 48% | 11.8× | -0.5% |
| Gan & Lee Pharmaceuticals 603087.SS | $5.59B | +11% | +14% | 20% | 25.8× | n/a |
| Lilly (Eli) LLY | $1.30T | +36% | +46% | 51% | 29.5× | 6.5% |
| Sanofi SAN.PA | $114B | +13% | +15% | 27% | 9.7× | -4.8% |
| United Laboratories International 3933.HK | $1.80B | -20% | -13% | 5% | 13.0× | 1.2% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 600867.SS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -1.7% | -5.5% | 9th highest of 21 |
| 6-month return | -12.4% | +2.3% | 8th lowest of 21 |
| Distance from 52-week high | -28.3% | -29.6% | 9th highest of 21 |
| Revenue growth (TTM) | +18.3% | +4.7% | 7th highest of 20 |
| Forward P/E | 25.4× | 17.5× | 6th most expensive of 15 |
| Growth the price implies (Req g, 7 yrs) | 0.9% | 2.8% | 6th least demanding of 15 |
| Growth delivered (Del g) | +0.3% | +13.1% | 3rd lowest of 15 |
| Hurdle (Req g minus delivered) | +0.5 pp | -0.9 pp | 7th most demanding of 15 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Tonghua Dongbao Pharmaceutical 600867.SS | China | $2.19B | -12% | +18% | n/a | 25.4× | 0.9% | +0.3% |
| Zhejiang Hisun Pharmaceutical 600267.SS | China | $2.19B | +14% | -7% | 15% | 15.0× | -9.7% | -1.5% |
| Alembic Pharmaceuticals APLLTD.NS | India | $2.20B | +39% | +20% | 12% | 25.0× | 26.7% | +6.5% |
| Shandong Buchang Pharmaceuticals 603858.SS | China | $2.25B | -7% | +4% | 10% | n/a | -2.5% | -5.8% |
| PharmaResearch 214450.KS | South Korea | $2.10B | -24% | +29% | 37% | 15.4× | -11.0% | +37.6% |
| Acrobiosystems 301080.SZ | China | $2.31B | +65% | +29% | 17% | 55.2× | 41.3% | +27.7% |
| Haw Par H02.SI | Singapore | $2.08B | -25% | -13% | 30% | 11.9× | 3.2% | +15.7% |
| Regencell Bioscience RGC | United States | $2.33B | -83% | n/a | n/a | n/a | n/a | n/a |
| InnoCare Pharma 688428.SS | China | $2.07B | -7% | +135% | 35% | 85.7× | -10.9% | +344.2% |
| Perrigo PRGO | United States | $2.35B | +52% | -4% | 5% | 6.7× | 14.1% | +0.8% |
| Sam Chun Dang Pharm 000250.KS | South Korea | $2.36B | -66% | +23% | 7% | n/a | n/a | n/a |
| Henan Lingrui Pharmaceutial 600285.SS | China | $2.04B | +9% | +5% | 22% | 15.9× | -4.7% | +10.6% |
| NewAmsterdam Pharma NAMS | United States | $2.37B | -45% | -26% | -900% | n/a | n/a | n/a |
| Nanjing King-friend Biochemical Pharmaceutical 603707.SS | China | $2.03B | -3% | +9% | 14% | 25.9× | 5.1% | +6.4% |
| Zhejiang Jiuzhou Pharmaceutical 603456.SS | China | $2.03B | +19% | -1% | 14% | 16.9× | 1.7% | +15.7% |
| HUTCHMED (China) 0013.HK | Hong Kong | $2.38B | +14% | -9% | -6% | 35.9× | 47.0% | +19.3% |
| Fujian Cosunter Pharmaceutical 300436.SZ | China | $2.02B | -45% | 0% | -47% | n/a | n/a | n/a |
| Keymed Biosciences 2162.HK | Hong Kong | $2.39B | +7% | 0% | -73% | 18.2× | n/a | n/a |
| InSilico Medicine Cayman TopCo 3696.HK | Hong Kong | $2.40B | -33% | +153% | -7% | 85.2× | 37.9% | +22.9% |
| Prestige Consumer Healthcare PBH | United States | $2.40B | +7% | +5% | 25% | 10.6× | 2.3% | +2.9% |
| Hanall Biopharma 009420.KS | South Korea | $2.01B | +12% | +5% | 3% | n/a | n/a | n/a |